Literature DB >> 34059683

The LINC01119-SOCS5 axis as a critical theranostic in triple-negative breast cancer.

Zhenbo Tu1, Johannes Schmoellerl1, Odette Mariani2, Yurong Zheng1, Yi Hu1, Anne Vincent-Salomon2, Antoine E Karnoub3,4,5.   

Abstract

The development of triple-negative breast cancer (TNBC) is critically regulated by certain tumor-microenvironment-associated cells called mesenchymal stem/stromal cells (MSCs), which we and others have shown promote TNBC progression by activating pro-malignant signaling in neighboring cancer cells. Characterization of these cascades would better our understanding of TNBC biology and bring about therapeutics that eliminate the morbidity and mortality associated with advanced disease. Here, we focused on the emerging class of RNAs called long non-coding RNAs or lncRNAs and utilized a MSC-supported TNBC progression model to identify specific family members of functional relevance to TNBC pathogenesis. Indeed, although some have been described to play functional roles in TNBC, activities of lncRNAs as mediators of tumor-microenvironment-driven TNBC development remain to be fully explored. We report that MSCs stimulate robust expression of LINC01119 in TNBC cells, which in turn induces suppressor of cytokine signaling 5 (SOCS5), leading to accelerated cancer cell growth and tumorigenesis. We show that LINC01119 and SOCS5 exhibit tight correlation across multiple breast cancer gene sets and that they are highly enriched in TNBC patient cohorts. Importantly, we present evidence that the LINC01119-SOCS5 axis represents a powerful prognostic indicator of adverse outcomes in TNBC patients, and demonstrate that its repression severely impairs cancer cell growth. Altogether, our findings identify LINC01119 as a major driver of TNBC development and delineate critical non-coding RNA theranostics of potential translational utility in the management of advanced TNBC, a class of tumors in most need of effective and targeted therapy.

Entities:  

Year:  2021        PMID: 34059683     DOI: 10.1038/s41523-021-00259-z

Source DB:  PubMed          Journal:  NPJ Breast Cancer        ISSN: 2374-4677


  60 in total

1.  Selection of bone metastasis seeds by mesenchymal signals in the primary tumor stroma.

Authors:  Xiang H-F Zhang; Xin Jin; Srinivas Malladi; Yilong Zou; Yong H Wen; Edi Brogi; Marcel Smid; John A Foekens; Joan Massagué
Journal:  Cell       Date:  2013-08-29       Impact factor: 41.582

Review 2.  Triple-negative breast cancer: disease entity or title of convenience?

Authors:  Lisa Carey; Eric Winer; Giuseppe Viale; David Cameron; Luca Gianni
Journal:  Nat Rev Clin Oncol       Date:  2010-09-28       Impact factor: 66.675

3.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.

Authors:  T Sørlie; C M Perou; R Tibshirani; T Aas; S Geisler; H Johnsen; T Hastie; M B Eisen; M van de Rijn; S S Jeffrey; T Thorsen; H Quist; J C Matese; P O Brown; D Botstein; P E Lønning; A L Børresen-Dale
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

4.  Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment.

Authors:  Pallavi Chaturvedi; Daniele M Gilkes; Naoharu Takano; Gregg L Semenza
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-05       Impact factor: 11.205

5.  Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

Authors:  Aditya Bardia; Ingrid A Mayer; Jennifer R Diamond; Rebecca L Moroose; Steven J Isakoff; Alexander N Starodub; Nikita C Shah; Joyce O'Shaughnessy; Kevin Kalinsky; Michael Guarino; Vandana Abramson; Dejan Juric; Sara M Tolaney; Jordan Berlin; Wells A Messersmith; Allyson J Ocean; William A Wegener; Pius Maliakal; Robert M Sharkey; Serengulam V Govindan; David M Goldenberg; Linda T Vahdat
Journal:  J Clin Oncol       Date:  2017-03-14       Impact factor: 44.544

6.  Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.

Authors:  Sandra M Swain; José Baselga; Sung-Bae Kim; Jungsil Ro; Vladimir Semiglazov; Mario Campone; Eva Ciruelos; Jean-Marc Ferrero; Andreas Schneeweiss; Sarah Heeson; Emma Clark; Graham Ross; Mark C Benyunes; Javier Cortés
Journal:  N Engl J Med       Date:  2015-02-19       Impact factor: 91.245

7.  Mesenchymal stem cells within tumour stroma promote breast cancer metastasis.

Authors:  Antoine E Karnoub; Ajeeta B Dash; Annie P Vo; Andrew Sullivan; Mary W Brooks; George W Bell; Andrea L Richardson; Kornelia Polyak; Ross Tubo; Robert A Weinberg
Journal:  Nature       Date:  2007-10-04       Impact factor: 49.962

8.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

9.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.

Authors:  Christina Curtis; Sohrab P Shah; Suet-Feung Chin; Gulisa Turashvili; Oscar M Rueda; Mark J Dunning; Doug Speed; Andy G Lynch; Shamith Samarajiwa; Yinyin Yuan; Stefan Gräf; Gavin Ha; Gholamreza Haffari; Ali Bashashati; Roslin Russell; Steven McKinney; Anita Langerød; Andrew Green; Elena Provenzano; Gordon Wishart; Sarah Pinder; Peter Watson; Florian Markowetz; Leigh Murphy; Ian Ellis; Arnie Purushotham; Anne-Lise Børresen-Dale; James D Brenton; Simon Tavaré; Carlos Caldas; Samuel Aparicio
Journal:  Nature       Date:  2012-04-18       Impact factor: 49.962

Review 10.  Breast Cancer Treatment: A Review.

Authors:  Adrienne G Waks; Eric P Winer
Journal:  JAMA       Date:  2019-01-22       Impact factor: 56.272

View more
  2 in total

1.  In Vitro and In Vivo Comparative Analysis of Differentially Expressed Genes and Signaling Pathways in Breast Cancer Cells on Interaction with Mesenchymal Stem Cells.

Authors:  Hariharan Jayaraman; Ashwin Anandhapadman; Nalinkanth Veerabadran Ghone
Journal:  Appl Biochem Biotechnol       Date:  2022-09-10       Impact factor: 3.094

Review 2.  Long Non-Coding RNAs in the Tumor Immune Microenvironment: Biological Properties and Therapeutic Potential.

Authors:  Ya-Nan Pi; Wen-Cai Qi; Bai-Rong Xia; Ge Lou; Wei-Lin Jin
Journal:  Front Immunol       Date:  2021-07-06       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.